Sidney Kimmel Cancer Center at Thomas Jefferson University Stands Out

Experts shared the key data that stood out in GU oncology at the 2026 ASCO Annual Meeting.

An OncLive workshop covered practice-changing ROS1- and ALK-directed data in NSCLC shared at ASCO 2026 and beyond.

Bringing some or all clinical trial-related activities directly to patients can help overcome barriers that prevent many people from participating.

Higher EO2463-induced CD8 T-cell expansion was associated with significantly longer PFS in indolent non-Hodgkin lymphoma.

Alpha DaRT plus pembrolizumab produced responses in all evaluable elderly patients with PD-L1–positive recurrent/metastatic head and neck cancer.

High CR/CRi rates were shown for olverembatinib plus blinatumomab in relapsed/refractory Ph-positive chronic myeloid leukemia and B-ALL.

PRAME-directed therapies represent a novel approach in the treatment of advanced melanoma.

Roswell Park Comprehensive Cancer Center investigators will deliver 21 presentations at the AHNS 12th International Conference on Head and Neck Cancer.